CorFlow Therapeutics is excited to announce a successful funding round, having raised an impressive $48.5 million to further its pioneering work in microvascular diagnostics and therapies. Founded in 2016 in Baar, Switzerland, CorFlow is on a mission to enhance cardiac care by addressing the critical issue of microvascular dysfunction and obstruction, which often goes undetected during traditional percutaneous coronary interventions (PCI). This innovative funding will accelerate the development of our groundbreaking diagnostic system designed to reveal microvascular obstruction (MVO) in real-time within the cath lab, enabling clinicians to proactively manage patient care. Currently under ongoing clinical studies, this investigational system aims to improve the efficacy and safety of cardiac interventions, ultimately contributing to better patient outcomes. Led by CEO Paul Mead, who has nearly two decades of medtech experience at Medtronic, and Chairman Rick Geoffrion of Cyrano Therapeutics, the company is committed to transforming the future of cardiology and beyond. CorFlow’s strategic vision is not only to lead the market in microvascular blood flow solutions but also to uphold values centered on quality, ethical standards, and inclusivity—all while addressing significant environmental, social, and governance goals. This latest funding round, bolstered by a combination of angel investors, venture capital, and Swiss government grants, positions CorFlow for an impactful Series B round targeted for later this year, reinforcing our relentless pursuit to meet unmet medical needs and extend the quality of human life. We’re thrilled about the next chapter in our journey and look forward to sharing our advancements with the medical community and patients alike.
CorFlow Therapeutics Secures 48.5M in Series B Funding to Revolutionize Microvascular Diagnosis and Treatment: Leading the Way in Cardiology Innovation
Recently funded · $48.5M Series bHealthcare
Get the full CorFlow Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Silicon Microgravity Ltd
Silicon Microgravity Limited (SMG) is a technology company focused on the inertial navigation and gravity markets. Over 10 years of research and development, first at Cambridge University's Nanoscience Department and then carried on inside SMG, has gone in to our resonant MEMS technology. Today SMG's team of scientists and engineers are based in our Technology Centre in Waterbeach, just north of Cambridge, England. SMG focuses on two markets. > Inertial navigation where our MEMS accelerometers and gyroscopes provide higher accuracy, smaller form factor and lower cost compared to existing sensors. > Gravity sensing where our MEMS gravimeters offer robust, compact solutions for gravity surveys and alternative navigation.
$7.7M Unknown
today
Applied Computing
Applied Computing; our vision is to deliver sustainable abundance for a growing planet, through AI that works for the Energy Industry. These industries are an enduring necessity, they power our planet, but their complexity has kept them tethered to legacy systems. These critical industries utilise less than 10% of their data for decision making and process optimisation. Our flagship product, Orbital, is a Multi-Foundation AI system that enables these industries to finally trust AI in the control room, harness 100% of their data and optimise in real time for any metric unlocking faster decisions, safer operations, and higher performance. With Orbital, we aim to transform how engineers and operators understand, and optimise their plants using trustworthy, physics-grounded AI. This isn’t the future of Industrial AI, this is the first time it’s worked.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  General Compute United States | Series b | $400.0M | today |
| 2 |  InDebted Australia | Series b | $25.0M | today |
